natgillin/translations-raw huggingface dataset:
Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/ or long-term exposure to combination antiretroviral therapy (CART).
Osteonekroza: čeprav je vzrokov verjetno več (vključno z uporabo kortikosteroidov, uživanjem alkohola, hudo imunosupresijo, višjim indeksom telesne mase), so o primerih osteonekroze poročali zlasti pri bolnikih z napredovalo boleznijo HIV in/ ali dolgotrajno izpostavljenostjo kombiniranemu protiretrovirusnemu zdravljenju (CART – combination antiretroviral therapy).
Since nelfinavir is highly bound to plasma proteins, it is unlikely that it will be significantly removed by haemodiaylisis or peritoneal dialysis.
Ledvična okvara: ker se nelfinavir močno veže na plazemske proteine, je malo verjetno, da se pomembno izloča s hemodializo ali peritonalno dializo.
Caution is advised whenever VIRACEPT is co- administered with medicinal products which are inducers or inhibitors and/ or substrates of CYP3A4; such combinations may require dose adjustment (see also sections 4.3, 4.5 and 4.8).
4 Kombinacija z drugimi zdravili: previdnost je potrebna pri jemanju zdravila VIRACEPT skupaj z zdravili, ki so induktorji ali zaviralci, in/ ali substrati za CYP3A4; takšne kombinacije lahko potrebujejo prilagoditev odmerka (glejte tudi poglavja 4. 3, 4. 5 in 4. 8).
The HMG (hydroxy-3-methyl-glutaryl) -CoA reductase inhibitors simvastatin and lovastatin are highly dependent on CYP3A4 for metabolism, thus concomitant use of VIRACEPT with simvastatin or lovastatin is not recommended due to an increased risk of myopathy including rhabdomyolysis.
Poveča se namreč tveganje za miopatijo, vključno z rabdomiolizo.
Caution must also be exercised if VIRACEPT is used concurrently with atorvastatin, which is metabolised to a lesser extent by CYP3A4.
Previdnost je potrebna tudi, če se zdravilo VIRACEPT uporablja skupaj z atorvastatinom, ki se prek CYP3A4 presnavlja v manjši meri.
In this situation a reduced dose of atorvastatin should be considered.
V tem primeru je treba razmisliti o zmanjšanju odmerka atorvastatina.
If treatment with a HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended (see section 4.5).
Če je potrebno zdravljenje z zaviralci HMG- CoA reduktaze, se priporočata pravastatin ali fluvastatin (glejte poglavje 4. 5).
Particular caution should be used when prescribing sildenafil in patients receiving PIs, including nelfinavir.
Pri bolnikih, ki jemljejo PI, vključno z nelfinavirjem, je pri predpisovanju sildenafila potrebna posebna previdnost.
Co-administration of a PI with sildenafil is expected to substantially increase sildenafil concentration and may result in an increase in sildenafil associated adverse events, including hypotension, visual changes, and priapism.
Pri sočasni uporabi PI s sildenafilom se pričakuje znatno povečanje koncentracij sildenafila, kar lahko privede do povečanega pojava s sildenafilom povezanih neželenih dogodkov, vključno s hipotenzijo, spremembami vida in priapizmom.
Potent inducers of CYP3A (e. g., phenobarbital and carbamazepine) may reduce nelfinavir plasma concentrations.
Močni induktorji CYP3A (npr. fenobarbital in karbamazepin) lahko zmanjšajo plazemske koncentracije nelfinavirja.
Physicians should consider using alternatives when a patient is taking VIRACEPT (see sections 4.3 and 4.5).
Če bolnik jemlje zdravilo VIRACEPT, morajo zdravniki razmisliti o drugih možnostih zdravljenja (glejte poglavji 4. 3 in 4. 5).
The absorption of nelfinavir may be reduced in situations where the gastric pH is increased irrespective of cause.
V primerih, kadar je pH v želodcu povišan neglede na vzrok, je lahko absorpcija nelfinavirja zmanjšana.
When nelfinavir is co-administered with omeprazole this may lead to a loss of virologic response and therefore concomitant use is contra-indicated (see section 4.3 and 4.5).
Pri sočasnem jemanju nelfinavirja z omeprazolom lahko pride do izgube virološkega odziva in zato je sočasno jemanje kontraindicirano (glejte poglavje 4. 3 in 4. 5).
Caution is recommended when nelfinavir is co-administered with other proton pump inhibitors (see section 4.5).
Pri sočasnem jemanju nelfinavirja z drugimi zaviralci protonske črpalke priporočamo previdnost (glejte poglavje 4. 5).
VIRACEPT may lead to a decreased AUC of phenytoin; therefore phenytoin concentrations should be monitored during concomitant use with VIRACEPT (see section 4.5).
Zdravilo VIRACEPT lahko povzroči zmanjšanje AUC fenitoina, zato je med sočasnim zdravljenjem z zdravilom VIRACEPT treba spremljati koncentracije fenitoina (glejte poglavje 4. 5).
Methadone AUC may be decreased when co-administered with VIRACEPT; therefore upward adjustment of methadone dose may be required during concomitant use with VIRACEPT (see section 4.5).
Med sočasnim zdravljenjem z zdravilom VIRACEPT bo morda treba zvišati odmerek metadona (glejte poglavje 4. 5).
Co-administration of the combination oral contraceptive containing norethindrone and 17 α -ethinylestradiol with VIRACEPT resulted in a decrease in AUC of the contraceptive -medicinal product.
Peroralni kontraceptivi: sočasno jemanje peroralnih kontraceptivov, ki vsebujejo noretindron in 17- α - etinilestradiol, z zdravilom VIRACEPT je povzročilo padec AUC kontracepcijskega zdravila.
Alternative contraceptive measures should therefore also be considered (see section 4.5).
Zato je treba razmisliti tudi o alternativni kontracepcijski zaščiti (glejte poglavje 4. 5).
New onset diabetes mellitus, hyperglycaemia or exacerbation of existing diabetes mellitus has been reported in patients receiving PIs.
Sladkorna bolezen in hiperglikemija: pri bolnikih, ki so jemali PI, so zasledili pojav sladkorne bolezni, hiperglikemijo ali poslabšanje obstoječe sladkorne bolezni.
There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in haemophiliac patients type A and B treated with PIs.
Bolniki z hemofilijo: pri bolnikih s hemofilijo tipa A in B, zdravljenih s PI, so se pojavile povečane krvavitve, vključno s spontanimi kožnimi hematomi, in krvavitvami v sklepe.
Combination antiretroviral therapy has been associated with the redistribution of body fat (lipodystrophy) in HIV patients.
Lipodistrofija: kombinirano protiretrovirusno zdravljenje je pri nekaterih bolnikih s HIV povezano s prerazporeditvijo telesne maščobe (lipodistrofija).
A connection between visceral lipomatosis and PIs and lipoatrophy and nucleoside analogue reverse transcriptase inhibitors (NRTIs) has been hypothesised.
Obstajajo hipoteze o povezavi med visceralno lipomatozo in PI ter lipoatrofijo in nukleozidnimi analogi zaviralcev reverzne transkriptaze (NRTI - “ nucleoside analogue reverse transcriptase inhibitors ”).
Clinical examination should include evaluation for physical signs of fat
Pri kliničnih pregledih je treba oceniti telesne znake prerazporeditve maščevja.
Consideration should be given to the measurement of fasting serum lipids and blood glucose.
5 Pomožne snovi: peroralni prašek VIRACEPT vsebuje sladilo aspartam (E951).
VIRACEPT oral powder contains aspartame (E951) as a sweetening agent.
Aspartam je izvor fenilalanina.
Aspartame provides a source of phenylalanine and, therefore, may not be suitable for persons with phenylketonuria.
Lahko škoduje ljudem s fenilketonurijo.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltese insufficiency should not take this medicine.
Bolniki z redko dedno intoleranco za fruktozo, malabsorbcijo glukoze/ galaktoze ali pomanjkanjem saharoza- izomaltaze ne smejo jemati tega zdravila.
See section 2 and 6.1 for further information on excipients.
Za dodatne informacije o pomožnih snoveh glejte tudi poglavje 2 in 6. 1.
Please refer to Table 1 and Table 2 for interactions of nelfinavir with selected compounds, Table 1 for impact on the pharmacokinetics of the co-administered compound, Table 2 for the impact of other drugs on pharmacokinetics of nelfinavir.
V preglednici 1 so opisani učinki nelfinavirja na farmakokinetiko sočasno dajanih zdravil, v preglednici 2 pa učinki sočasno dajanih zdravil na farmakokinetiko nelfinavirja.
Nelfinavir is primarily metabolised via the cytochrome P450 isoenzymes CYP3A and CYP2C19 (see section 5.2).
Nelfinavir se v glavnem presnavlja z izoencimi CYP3A in CYP2C19 citokroma P450 (glejte poglavje 5. 2).
Co-administration with the following medicinal products that are substrates for CYP3A4 and which have narrow therapeutic windows is contraindicated (see section 4.3 and below): terfenadine, astemizole, cisapride, amiodarone, quinidine, ergot derivatives, pimozide, oral midazolam and triazolam.
Sočasno jemanje sledečih zdravil, ki so substrati za CYP3A4 in ki imajo ozko terapevtsko okno, je kontraindicirano (glejte poglavje 4. 3 in spodnje besedilo): terfenadin, astemizol, cisaprid, amiodaron, kvinidin, derivati ergot, pimozid, triazolam, peroralni midazolam.
Caution should be used when co-administering medicinal products that induce CYP3A or potentially toxic medicinal products which are themselves metabolised by CYP3A (see section 4.3 and below).
Pri sočasni uporabi zdravil, ki inducirajo CYP3A, ali potencialno toksičnih zdravil, ki se presnavljajo s CYP3A, je potrebna previdnost (glejte poglavje 4. 3 in spodnje besedilo).
Other antiretrovirals:
Druga protiretrovirusna zdravila:
Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs):
Nukleozidni analogi zaviralcev reverzne transkriptaze (NRTI)
Clinically significant interactions have not been observed between nelfinavir and nucleoside analogues (specifically zidovudine plus lamivudine, stavudine, and stavudine plus didanosine).
Klinično pomembnih medsebojnih delovanj med nelfinavirjem in nukleozidnimi analogi (posebno kombinacije zidovudin in lavimudin, stavudin ter stavudin in didanozin) niso opazili.
At present, there is no evidence of inadequate efficacy of zidovudine in the CNS that could be associated with the modest reduction in plasma levels of zidovudine when co-administered with nelfinavir.
Za zdaj ni dokazov za nezadostno učinkovitost zidovudina v CŽS, ki bi jih lahko povezovali z blagim zmanjšanjem koncentracij zidovudina v plazmi ob sočasnem uživanju nelfinavirja.
Other Protease Inhibitors (PIs):
Drugi proteazni zaviralci (PI)
There were no significant differences between low doses of ritonavir (either 100 or 200 mg BID) for effects on AUCs of nelfinavir and M8.
Ritonavir: med nizkimi odmerki ritonavirja (100 mg ali 200 mg dvakrat na dan) ni bilo bistvenih razlik v vplivu na AUC nelfinavirja in M8.
The clinical relevance of these findings has not been established.
Klinični pomen teh ugotovitev še ni raziskan.
See Tables 1 and 2 for more information.
Za več informacij glejte preglednici 1 in 2.
The safety of this combination has not been established.
Indinavir: varnosti te kombinacije niso ugotovili.
See Tables 1 and 2 for more information.
Mehke želatinske kapsule sakvinavirja: za več informacij glejte preglednici 1 in 2.
No dose adjustment is necessary for either medicinal product when nelfinavir is administered in combination with amprenavir.
Amprenavir: kadar se jemlje nelfinavir v kombinaciji z amprenavirjem, ni treba prilagajati odmerka za nobeno od teh dveh zdravil.
6 Non-nucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs):
Nenukleozidni analogi zaviralcev reverzne transkriptaze (NNRTI – “ Non- nucleoside analogue reverse transcriptase inhibitors ”)
A dose adjustment is not needed when efavirenz is administered with VIRACEPT.
Efavirenz: pri sočasnem jemanju zdravila VIRACEPT in efavirenza odmerkov ni treba prilagajati.
The safety of this drug combination has not been established and this combination is not recommended.
Delavirdin: varnost kombinacije še ni bila ugotovljena, zato jemanja te kombinacije ne priporočamo.
A dose adjustment is not needed when nevirapine is administered with VIRACEPT.
6 Nevirapin: med sočasnim jemanjem zdravila VIRACEPT in nevirapina prilagajanje odmerkov ni potrebno.
Metabolic enzyme inducers: rifampicin decreases nelfinavir plasma AUC by 82% and its concomitant use with nelfinavir is contraindicated (see section 4.3).
Induktorji presnovnih encimov: rifampicin zmanjša AUC nelfinavirja v plazmi za 82%, njegova sočasna uporaba z nelfinavirjem je kontraindicirana (glejte poglavje 4. 3).
Other potent inducers of CYP3A (e. g., phenobarbital, carbamazepine) may also reduce nelfinavir plasma concentrations.
Drugi močni induktorji CYP3A (npr. fenobarbital, karbamazepin) prav tako lahko znižajo koncentracije nelfinavirja v plazmi.
If therapy with such medicinal products is warranted, physicians should consider using alternatives when a patient is taking VIRACEPT.
Če se bolnik s temi zdravili že zdravi, mora zdravnik ob sočasnem jemanju zdravila VIRACEPT proučiti možnost uporabe drugih zdravil.
Dosage reduction of rifabutin to 150 mg once a day is necessary when nelfinavir 750 mg TID or 1250 mg BID and rifabutin are co-administered.
Rifabutin: pri sočasnem jemanju nelfinavirja 750 mg trikrat na dan ali 1. 250 mg dvakrat na dan in rifabutina je treba nujno zmanjšati odmerek rifabutina na 150 mg enkrat na dan.
Co-administration of nelfinavir 1250 mg BID with phenytoin 300 mg once a day did not change the concentration of nelfinavir.
Fenitoin: pri sočasnem jemanju nelfinavirja po 1. 250 mg dvakrat na dan s fenitoinom po 300 mg enkrat na dan ni prišlo do sprememb koncentracije nelfinavirja.
However, AUC values of phenytoin and free phenytoin were reduced by 29% and 28% by co-administration of nelfinavir, respectively.
Vendar pa so se pri sočasnem jemanju z nelfinavirjem znižale vrednosti AUC fenitoina in prostega fenitoina za 29% in 28%.
No dose adjustment for nelfinavir is recommended.
Prilagajanje odmerkov nelfinavirja ni potrebno.
Phenytoin concentrations should be monitored during co-administration with nelfinavir.
Med sočasnim jemanjem nelfinavirja in fenitoina je treba spremljati koncentracije fenitoina.
John’ s wort (Hypericum perforatum).
Šentjanževka (Hypericum perforatum): pri sočasni uporabi pripravka rastlinskega izvora, ki vsebuje šentjanževko (Hypericum perforatum) in nelfinavirja se lahko zmanjšajo koncentracije nelfinavirja v plazmi.
John’ s wort.
Šentjanževka inducira encime, ki presnavljajo učinkovino, in/ ali transportne proteine.
If a patient is already taking St.
Pripravki rastlinskega izvora, ki vsebujejo šentjanževko, se sočasno z zdravilom VIRACEPT ne smejo uporabljati.
John’ s wort, check viral levels and if possible nelfinavir levels.
Če bolnik že jemlje šentjanževko, naj z njenim jemanjem prekine, preveriti pa je treba virusno koncentracijo in, če je mogoče, koncentracije nelfinavirja.
John’ s wort, and the dose of VIRACEPT may need adjusting.
Po prekinitvi jemanja šentjanževke lahko pride do porasta koncentracij nelfinavirja in zato bo morda treba prilagoditi odmerek zdravila VIRACEPT.
John’ s wort may persist for at least 2 weeks after cessation of treatment (see section 4.3).
Induktivni učinek šentjanževke na encime lahko traja vsaj še 2 tedna po prekinitvi zdravljenja s šentjanževko (glejte poglavje 4. 3).
Metabolic enzyme inhibitors: co-administration of nelfinavir and a strong inhibitor of CYP3A, ketoconazole, resulted in a 35% increase in nelfinavir plasma AUC.
Zaviralci presnovnih encimov: sočasno jemanje nelfinavirja in močnega zaviralca CYP3A, ketokonazola, povzroči 35% porast AUC nelfinavirja v plazmi.
This change is not considered clinically significant and no dose adjustment is needed when ketoconazole and VIRACEPT are co-administered.
Ta sprememba ni klinično pomembna in prilagajanje odmerkov ob sočasnem jemanju ketokonazola in zdravila VIRACEPT ni potrebno.
Based on the metabolic profiles, a clinically relevant drug interaction would not be expected with other specific inhibitors of CYP3A (e. g., fluconazole, itraconazole, clarithromycin, erythromycin); however, the possibility cannot be excluded.
Na podlagi presnovnih profilov tudi z drugimi specifičnimi zaviralci CYP3A (npr. s flukonazolom, itrakonazolom, klaritromicinom, eritromicinom) ni pričakovati klinično pomembnih medsebojnih delovanj, vendar pa možnosti ne moremo izključiti.
Co-administration of nelfinavir with inhibitors of CYP2C19 (e. g., fluconazole, fluoxetine, paroxetine, lansoprazole, imipramine, amitriptyline and diazepam) may be expected to reduce the conversion of nelfinavir to its major active metabolite M8 (tert-butyl hydroxy nelfinavir) with a concomitant increase in plasma nelfinavir levels (see section 5.2).
Sočasno jemanje nelfinavirja z zaviralci CYP2C19 (npr. flukonazol, fluoksetin, paroksetin, lansoprazol, imipramin, amitriptilin in diazepam) lahko zmanjša pretvorbo nelfinavirja v njegov glavni aktivni presnovek M8 (terc- butil hidroksinelfinavir) in posledično poveča koncentracije nelfinavirja v plazmi (glejte poglavje 5. 2).
Co-administration of omeprazole (20 mg twice daily) and Viracept (1250 mg twice daily) to 19 healthy volunteers for 4 days resulted in reduced mean nelfinavir AUC by 36%, mean Cmax by 37%, and mean Cmin by 39%.
Omeprazol: pri 19 zdravih prostovoljcih, ki so 4 dni sočasno prejemali omeprazol (20 mg dvakrat na dan) in zdravilo Viracept (1250 mg dvakrat na dan), je prišlo do zmanjšanja srednje AUC nelfinavirja za 36%, srednje Cmax za 37% in srednje Cmin za 39%.
Reductions were observed in the mean M8 AUC by 92%, mean Cmax by 89%, and mean Cmin by 75%.
Srednja AUC M8 je bila manjša za 92%, srednja Cmax za 89%, srednja Cmin za 75%.
Therefore omeprazole should not be co-administered with VIRACEPT (see section 4.3)
Omeprazola zato ne smemo sočasno dajati z zdravilom VIRACEPT (glejte poglavje 4. 3).
7 The absorption of nelfinavir may be reduced in conditions where gastric pH is increased, therefore concomitant use of VIRACEPT with Proton Pump Inhibitors is not recommended (see section 4.4), except for omeprazole which is contra-indicated (see section 4.3).
Sočasna uporaba z omeprazolom je kontraindicirana (glejte poglavje 4. 3).
HMG-CoA reductase inhibitors which are highly dependent on CYP3A4 metabolism, such as lovastatin and simvastatin, are expected to have markedly increased plasma concentrations when co-administered with VIRACEPT.
Pri zaviralcih HMG- CoA reduktaze, katerih presnova je močno odvisna od CYP3A4, kot sta lovastatin in simvastatin, pričakujejo močno povišanje koncentracije v plazmi pri sočasnem jemanju z zdravilom VIRACEPT.
Since increased concentrations of HMG-CoA reductase inhibitors may cause myopathy, including rhabdomyolysis, the combination of these medicinal products with VIRACEPT is not recommended.
7 Ker povečana koncentracija zaviralcev HMG- CoA reduktaze lahko povzroči miopatijo, vključno z rabdomiolizo, kombinacija teh zaviralcev z zdravilom VIRACEPT ni priporočljiva.
When used with VIRACEPT, the lowest possible dose of atorvastatin should be administered.
Pri sočasnem jemanju zdravila VIRACEPT in atorvastatina je treba dati najnižji možni odmerek atorvastatina.
The metabolism of pravastatin and fluvastatin is not dependent on CYP3A4, and interactions are not expected with PIs.
Presnova pravastatina in fluvastatina ni odvisna od CYP3A4, zato ni pričakovati medsebojnega delovanja s PI.
If treatment with a HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.
Če je potrebno zdravljenje z zaviralci HMG- CoA reduktaze, se priporočata pravastatin in fluvastatin.
Co-administration of nelfinavir 1250 mg BID with methadone 80 +/ - 21 mg once a day in HIV negative methadone maintenance patients resulted in a 47% decrease in methadone AUC.
Metadon: pri sočasnem jemanju nelfinavirja v odmerku 1. 250 mg dvakrat na dan in metadona v odmerku 80 + / - 21 mg enkrat na dan, je pri HIV negativnih bolnikih, ki so se zdravili z metadonom, prišlo do 47% zmanjšanja AUC metadona.
None of the subjects experienced withdrawal symptoms in this study; however, due to the pharmacokinetic changes, it should be expected that some patients who received this drug combination may experience withdrawal symptoms and require an upward adjustment of the methadone dose.
V tem primeru je treba zvečati odmerek metadona.
Nelfinavir increases terfenadine plasma concentrations; therefore, VIRACEPT must not be administered concurrently with terfenadine because of the potential for serious and/ or life-threatening cardiac arrhythmias.
Druga možna medsebojna delovanja (glejte tudi poglavje 4. 3): nelfinavir poveča koncentracije terfenadina v plazmi, zato zdravila VIRACEPT zaradi možnosti resnih in/ ali življenjsko nevarnih srčnih aritmij ne smemo jemati skupaj s terfenadinom.
Because similar interactions are likely with astemizole and cisapride, VIRACEPT must not be administered concurrently with these drugs.
Zaradi podobnih možnih medsebojnih delovanj z astemizolom in cisapridom zdravila VIRACEPT tudi z njima ne smemo jemati.
Co-administration with VIRACEPT may cause a large increase in the concentration of this benzodiazepine.
Sočasno dajanje midazolama z zdravilom VIRACEPT lahko v veliki meri poviša koncentracijo tega benzodiazepina.
No drug interaction study has been performed for the co-administration of VIRACEPT with benzodiazepines.
O sočasnem dajanju zdravila VIRACEPT z benzodiazepini ni bilo izvedenih študij medsebojnega delovanja.
Based on data for other CYP3A4 inhibitors, plasma concentrations of midazolam are expected to be significantly higher when midazolam is given orally.
Na osnovi podatkov drugih zaviralcev CYP3A4 je pričakovati, da bodo plazemske koncentracije midazolama značilno višje pri peroralnem dajanju.
Therefore VIRACEPT should not be co-administered with orally administered midazolam (see section 4.3), whereas caution should be used with co-administration of VIRACEPT and parenteral midazolam.
Zdravila VIRACEPT zato ne smemo dajati sočasno z midazolamom, danim peroralno (glejte poglavje 4. 3), pri sočasnem jemanju s parenteralno danim midazolamom pa je potrebna previdnost.
Data from concomitant use of parenteral midazolam with other protease inhibitors suggest a possible 3-4 fold increase in midazolam plasma levels.
Podatki o sočasni uporabi parenteralnega midazolama z drugimi zaviralci proteaz kažejo na možno 3 do 4- kratno povečanje plazemskih koncentracij midazolama.
If VIRACEPT is co-administered with parenteral midazolam, it should be done in an intensive care unit (ICU) or similar setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/ or prolonged sedation.
Če se zdravilo VIRACEPT daje sočasno s parenteralno obliko midazolama, se mora to izvesti v enoti za intenzivno nego ali podobnem okolju, ki zagotavlja natančno klinično spremljanje in ustrezno medicinsko oskrbo v primeru respiratorne depresije in/ ali podaljšane sedacije.
Dosage adjustment for midazolam should be considered, especially if more than a single dose of midazolam is administered.
Razmisliti je treba o prilagoditvi odmerka midazolama, zlasti, če je bil dan več kot en odmerek midazolama.
Similarly, concomitant administration of nelfinavir with any of amiodarone, quinidine, pimozide and ergot derivatives is contraindicated.
Podobno je sočasno jemanje nelfinavirja z amiodaronom, kvinidinom, pimozidom in ergot derivati kontraindicirano.
For other compounds that are substrates for CYP3A (e. g., calcium channel blockers including bepridil, immunosuppressants including tacrolimus and ciclosporin, and sildenafil) plasma concentrations may be elevated when co-administered with VIRACEPT; therefore, patients should be monitored for toxicities associated with such medicinal products.
Zato je treba pri bolnikih, ki jemljejo taka zdravila, nadzorovati toksičnost, ki bi bila lahko povezana s temi zdravili.